Cutaneous and noncutaneous disorders treated with extracorporeal photopheresis

Reduced alloimmunization in mice following repeated transfusion with pathogen‐reduced platelets

“…UV light has been used in other systems to induce tolerance both to autoantigens and alloantigens. Extracorporeal photochemotherapy, in which a patient's own WBCs are collected by apheresis, treated with a photoactivator (8‐methoxypsoralen) and UVA light, and then returned into circulation, has been used to treat both autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, or alloresponses such as solid organ transplant rejection or graft‐versus‐host disease . The immunosuppressive impact of extracorporeal photochemotherapy is associated with induction of a tolerogenic phenotype in dendritic cells and increased regulatory T cells, most likely induced by uptake of apoptotic cells generated by the UV exposure .…”

Apoptosis: A target for potentiation of UV-induced IL-1Ra synthesis by IVIg

“…Photochemotherapy which combines 8-MOP to UVA irradiation of patient's PBMC [36] initially used for treatment of cutaneous T-cell lymphoma [37] has been applied in various autoimmune [37] and alloimmune conditions such as GVH occurring after stem cell transplantation [38] characterized by resistance to conventional immunosuppression. Although significant, the amplitude of action of this form of immunotherapy is generally modest.…”

Extracorporeal photochemotherapy in patients with cutaneous T‐cell lymphoma: is clinical response predictable?

“…Phagocytosis of lymphoma cells has been supposed to result in production of specific T-suppressor cells acting against clonal T cells. [26][27][28][29][30] Berger et al have demonstrated through their research that CTCL may be a malignant proliferation of T-regulatory (T-reg) cells, i.e. cells expressing a T-regulatory phenotype (CD25+, CTLA-4+, FoxP3+) being stimulated by dendritic cells loaded with apoptotic CTCL cells.…”